NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: These CML-derived iPS cells maintained expression of the oncogenic BCR-ABL fusion transcript (encoding a constitutively active, mutant tyrosine kinase), yet exhibited resistance to the receptor tyrosine kinase inhibitor, imatinib.